|
|
|
Insider
Information: |
Bienaime Jean Jacques |
Relationship: |
|
City: |
Palo Alto |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
539,854 |
|
Indirect Shares
|
247,533 |
|
|
Direct
Value |
$43,079,680 |
|
|
Indirect Value
|
$21,938,850 |
|
|
Total
Shares |
787,387 |
|
|
Total
Value |
$65,018,530 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
2
|
1
|
Stock
price went up :
|
1
|
0
|
Stock
price went down : |
1
|
1
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
Percentage
Gain/Loss : |
-13.1%
|
-5.5%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2024-05-20 |
473,792 |
2024-05-20 |
247,533 |
Premium* |
|
Neurogesx Inc |
NGSX |
Director |
2011-07-26 |
21,748 |
|
0 |
Premium* |
|
InterMune Inc |
ITMN |
Director |
2014-09-29 |
0 |
2012-04-06 |
0 |
Premium* |
|
Portola Pharmaceuticals Inc |
PTLA |
Director |
2014-05-16 |
706 |
2013-05-28 |
0 |
Premium* |
|
Immunic Inc |
IMUX |
Director |
2018-09-24 |
18,500 |
2001-04-23 |
0 |
Premium* |
|
Incyte Corp |
INCY |
Director |
2023-06-14 |
15,493 |
|
0 |
Premium* |
|
Immunome Inc. |
IMNM |
|
2024-05-21 |
9,615 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
852 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 27 of 35
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-04-14 |
4 |
OE |
$37.46 |
$374,600 |
D/D |
10,000 |
344,983 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-05-05 |
4 |
AS |
$84.14 |
$841,400 |
D/D |
(10,000) |
335,324 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2022-05-05 |
4 |
OE |
$37.46 |
$374,600 |
D/D |
10,000 |
345,324 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-01-13 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
330,424 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-01-13 |
4 |
AS |
$112.25 |
$1,122,500 |
D/D |
(10,000) |
320,424 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-01-17 |
4 |
AS |
$111.55 |
$1,115,500 |
D/D |
(10,000) |
320,424 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-01-17 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
330,424 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-04-06 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
435,896 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-04-06 |
4 |
AS |
$96.13 |
$961,300 |
D/D |
(10,000) |
425,896 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-04-10 |
4 |
AS |
$99.56 |
$995,600 |
D/D |
(10,000) |
425,896 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2023-04-10 |
4 |
OE |
$67.81 |
$678,100 |
D/D |
10,000 |
435,896 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Director |
|
2023-12-21 |
4 |
AS |
$93.99 |
$939,900 |
D/D |
(10,000) |
425,112 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Director |
|
2023-12-21 |
4 |
OE |
$63.10 |
$631,000 |
D/D |
10,000 |
435,112 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Director |
|
2024-01-09 |
4 |
OE |
$63.10 |
$631,000 |
D/D |
10,000 |
435,162 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Director |
|
2024-01-09 |
4 |
AS |
$98.19 |
$981,900 |
D/D |
(10,000) |
425,162 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Director |
|
2024-01-10 |
4 |
OE |
$63.10 |
$631,000 |
D/D |
10,000 |
435,162 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Director |
|
2024-01-10 |
4 |
AS |
$96.38 |
$963,800 |
D/D |
(10,000) |
425,162 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2008-05-02 |
4 |
AS |
$36.50 |
$376,050 |
D/D |
(10,100) |
8,567 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2013-05-23 |
4 |
GA |
$0.00 |
$0 |
I/I |
10,131 |
40,740 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2013-05-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,131 |
115,770 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-10-14 |
4 |
AS |
$86.89 |
$955,814 |
D/D |
(11,000) |
323,368 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2016-10-14 |
4 |
OE |
$17.86 |
$196,460 |
D/D |
11,000 |
334,368 |
0 |
- |
|
NGSX |
Neurogesx Inc |
Director |
|
2011-07-26 |
4 |
A |
$1.65 |
$19,185 |
D/D |
11,627 |
21,748 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2013-03-26 |
4 |
AS |
$60.68 |
$728,147 |
I/I |
(12,000) |
13,545 |
0 |
- |
|
BMRN |
Biomarin Pharmaceutical I... |
Chief Executive Officer |
|
2013-03-26 |
4 |
OE |
$12.99 |
$155,880 |
I/I |
12,000 |
25,545 |
0 |
- |
|
852 Records found
|
|
Page 27 of 35 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|